HK1035331A1 - Liposome composition and method for administering a quinolone. - Google Patents

Liposome composition and method for administering a quinolone.

Info

Publication number
HK1035331A1
HK1035331A1 HK01106151A HK01106151A HK1035331A1 HK 1035331 A1 HK1035331 A1 HK 1035331A1 HK 01106151 A HK01106151 A HK 01106151A HK 01106151 A HK01106151 A HK 01106151A HK 1035331 A1 HK1035331 A1 HK 1035331A1
Authority
HK
Hong Kong
Prior art keywords
liposome composition
quinolone
administering
composition
ciprofloxacin
Prior art date
Application number
HK01106151A
Other languages
English (en)
Inventor
Luke S S Guo
Josh Gittelman
Samuel Zalipsky
Francis J Martin
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of HK1035331A1 publication Critical patent/HK1035331A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK01106151A 1998-04-02 2001-08-31 Liposome composition and method for administering a quinolone. HK1035331A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/054,857 US5972379A (en) 1995-02-14 1998-04-02 Liposome composition and method for administering a quinolone
PCT/US1999/006500 WO1999051202A2 (en) 1998-04-02 1999-03-24 Quinolone containing liposomes and their use as antibacterial agents

Publications (1)

Publication Number Publication Date
HK1035331A1 true HK1035331A1 (en) 2001-11-23

Family

ID=21993954

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01106151A HK1035331A1 (en) 1998-04-02 2001-08-31 Liposome composition and method for administering a quinolone.

Country Status (17)

Country Link
US (1) US5972379A (da)
EP (1) EP1083881B1 (da)
JP (1) JP2002510611A (da)
KR (1) KR100617921B1 (da)
CN (1) CN1149978C (da)
AT (1) ATE274342T1 (da)
AU (1) AU763989B2 (da)
CA (1) CA2326497A1 (da)
DE (1) DE69919698T2 (da)
DK (1) DK1083881T3 (da)
ES (1) ES2226371T3 (da)
HK (1) HK1035331A1 (da)
IL (1) IL138685A0 (da)
NZ (1) NZ506970A (da)
PT (1) PT1083881E (da)
WO (1) WO1999051202A2 (da)
ZA (1) ZA200005333B (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US20030147944A1 (en) * 1999-12-10 2003-08-07 Mayer Lawrence D Lipid carrier compositions with protected surface reactive functions
ATE309786T1 (de) 2000-06-30 2005-12-15 Inex Pharmaceuticals Corp Liposomale antineoplastische arzneimittel und deren verwendungen
US7452550B2 (en) 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
HUP0400171A2 (en) * 2001-06-01 2007-02-28 Astellas Pharma Europ B V Lipid-polymer-conjugates
AU2002334358B2 (en) * 2001-09-06 2008-02-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparing liposome formulations with a predefined release profile
US20040219201A1 (en) * 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
EP1482789A4 (en) * 2002-03-12 2010-12-29 Toyama Chemical Company Ltd TASTY ORAL SUSPENSION AND METHOD
CA2504317C (en) * 2002-10-29 2012-05-22 Transave, Inc. Sustained release of antiinfectives
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
WO2004110493A2 (en) * 2003-05-30 2004-12-23 Alza Corporation Method of pulmonary administration of an agent
CN100431525C (zh) * 2003-07-17 2008-11-12 台湾东洋药品工业股份有限公司 脂质体悬浮液制造方法及含该法所制脂质体悬浮液的产物
US7589233B2 (en) * 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) * 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
WO2005046575A2 (en) * 2003-07-29 2005-05-26 Signature R & D Holdings, Lcc Amino acid prodrugs
US7915223B2 (en) * 2004-09-27 2011-03-29 Technion Research & Development Foundation Ltd. Antimicrobial agents
AU2005292083A1 (en) * 2004-09-29 2006-04-13 Alza Corporation Microparticles and nanoparticles containing a lipopolymer
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
CN100403535C (zh) * 2005-05-18 2008-07-16 崇贸科技股份有限公司 可控制触发电压的静电放电装置
EP3067047B1 (en) 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8071127B2 (en) 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
KR100916160B1 (ko) * 2007-02-21 2009-09-08 (주)바이오버드 약제학적 항암 조성물
US20100173832A1 (en) * 2007-04-30 2010-07-08 Technion Research & Development Foundation Ltd. Anticancerous polymeric agents
EP2152289A1 (en) * 2007-04-30 2010-02-17 Technion Research & Development Foundation Ltd. Novel antimicrobial agents
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
WO2011038073A1 (en) * 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes comprising docetaxel
CN102309448B (zh) * 2010-06-29 2014-07-09 中国人民解放军军事医学科学院毒物药物研究所 一种肺部给药的环丙沙星药用组合物及其制备方法
CN102188430B (zh) * 2011-04-06 2012-08-15 广东如来医药进出口有限公司 司帕沙星化合物的组合物制剂及其制备方法
NZ719739A (en) 2012-05-21 2017-07-28 Insmed Inc Systems for treating pulmonary infections
KR102186116B1 (ko) 2012-11-20 2020-12-03 스펙트럼 파마슈티컬즈 인크 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법
EP3581186A1 (en) 2012-11-29 2019-12-18 Insmed Incorporated Stabilized vancomycin formulations
US9987227B2 (en) 2013-10-22 2018-06-05 Aradigm Corporation Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
PT3142643T (pt) 2014-05-15 2019-10-28 Insmed Inc Métodos para o tratamento de infeções mico bacterianas pulmonares não tuberculares
EP2957561A1 (en) * 2014-06-18 2015-12-23 Université Paris 6 Pierre et Marie Curie UPMC Novel fluoroquinolones and use thereof to treat bacterial infections
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
GB2552301A (en) * 2016-07-11 2018-01-24 Evox Therapeutics Ltd Metabolic drug loading of EVs
US20170172921A1 (en) * 2016-12-14 2017-06-22 Mahmoud Reza Jaafari Polyphenolic compounds encapsualated in long circulating liposomes and use thereof
KR102337566B1 (ko) * 2017-07-24 2021-12-14 파모사 바이오팜 인코포레이티드 약산성 약물을 포함하는 리포솜 조성물 및 이의 용도
CN109305987B (zh) * 2017-07-27 2021-04-20 济南大学 环丙沙星金属配合物及其制备方法和应用
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
ATE63124T1 (de) * 1986-03-14 1991-05-15 Fujisawa Pharmaceutical Co Prodrugverbindungen, verfahren zu deren herstellung und diese enthaltende zubereitungen mit verzoegerter freisetzung.
US5057523A (en) * 1988-09-22 1991-10-15 Abbott Laboratories Dipeptide quinolone derivatives
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
WO1991009616A1 (en) * 1989-12-22 1991-07-11 Yale University Quinolone antibiotics encapsulated in lipid vesicles
CA2087965A1 (en) * 1990-07-30 1992-02-01 Ajoy Chakrabarti Accumulation of amino acids and peptides into liposomes
CA2101241C (en) * 1993-07-23 1998-12-22 Jonathan P. Wong Liposome-encapsulated ciprofloxacin
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
AU4981896A (en) * 1995-02-14 1996-09-04 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering liposome-loadable drugs
US5800833A (en) * 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
CA2263455C (en) * 1996-08-23 2002-10-29 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US5837282A (en) * 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading

Also Published As

Publication number Publication date
ATE274342T1 (de) 2004-09-15
EP1083881A2 (en) 2001-03-21
US5972379A (en) 1999-10-26
IL138685A0 (en) 2001-10-31
CN1295465A (zh) 2001-05-16
AU763989B2 (en) 2003-08-07
AU3453399A (en) 1999-10-25
CN1149978C (zh) 2004-05-19
KR100617921B1 (ko) 2006-08-30
JP2002510611A (ja) 2002-04-09
ZA200005333B (en) 2001-10-31
PT1083881E (pt) 2004-11-30
CA2326497A1 (en) 1999-10-14
WO1999051202A3 (en) 1999-11-18
EP1083881B1 (en) 2004-08-25
KR20010034727A (ko) 2001-04-25
DK1083881T3 (da) 2005-01-03
WO1999051202A2 (en) 1999-10-14
DE69919698D1 (de) 2004-09-30
ES2226371T3 (es) 2005-03-16
DE69919698T2 (de) 2005-05-25
NZ506970A (en) 2003-07-25

Similar Documents

Publication Publication Date Title
HK1035331A1 (en) Liposome composition and method for administering a quinolone.
IL142573A0 (en) Liposome-entrapped topoisomerase inhibitors
ATE252372T1 (de) Liposome enthaltend cisplatin
IL122386A0 (en) Anti-fungal and anti-bacterial histatin-based peptides
IL130823A0 (en) Peptide-lipid conjugates liposomes and liposomal drug delivery
MXPA03010448A (es) Metodo y composicion para reducir la union de bacterias a biomateriales.
EP0955044A3 (en) Method of inhibiting bacterial or fungal growth using a complexing agent
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
EP0828779A4 (en) WATER-SOLUBLE POLYMERS AND COMPOSITIONS THEREOF
AU6368494A (en) Enhanced circulation effector composition and method
AU6339599A (en) Quinoline derivatives and their use as antibacterial agents
ZA988278B (en) Ionic polymers as toxin-binding agents
ATE241351T1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
IE863104L (en) Quinolone derivatives
EP1140022B8 (en) Method of administering a compound to multi-drug resistant cells
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
NZ263740A (en) Ionene polymers as anthelmintics
EP1162956B8 (en) Compositions and methods for improving integrity of compromised body passageways and cavities
DE69813200D1 (de) Verbesserung der wundheilung mit cm101/gbs-toxin
BR0212143A (pt) Composição para lavagem bucal para tratamento ou prevenção de infecção por bactérias ou fungos
AU2001226361A1 (en) Pharmaceutical composition and method of using the same
WO1999065511A3 (en) Composition and method for treatment of pseudomonas infection
AU2067297A (en) Method for treating substance abuse
HUP9902828A3 (en) Pharmaceutical composition for killing antibiotic-resistant gram positive bacteria and treatment of infection
MX9709262A (es) Polimeros solubles en agua y composiciones de los mismos.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090324